MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy

ClinicalTrials.gov ID: NCT01294306

Public ClinicalTrials.gov record NCT01294306. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jun 25, 2026, 7:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy

Study identification

NCT ID: NCT01294306
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: National Cancer Institute (NCI); NIH
Enrollment: 80 participants

Conditions and interventions

Conditions

Interventions

Akt Inhibitor MK2206 Drug
Erlotinib Hydrochloride Drug
Laboratory Biomarker Analysis Other
Pharmacological Study Other

Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 31, 2011
Primary completion: Jul 31, 2015
Completion: Jul 31, 2015
Last update posted: Nov 28, 2016

2011 – 2015

United States locations

U.S. sites: 7
U.S. states: 3
U.S. cities: 7

Facility	City	State	ZIP	Site status
Tower Cancer Research Foundation	Beverly Hills	California	90211-1850	—
City of Hope Comprehensive Cancer Center	Duarte	California	91010	—
USC / Norris Comprehensive Cancer Center	Los Angeles	California	90033	—
University of California Davis Comprehensive Cancer Center	Sacramento	California	95817	—
City of Hope South Pasadena	South Pasadena	California	91030	—
University of Chicago Comprehensive Cancer Center	Chicago	Illinois	60637	—
University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh	Pennsylvania	15232	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01294306, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 28, 2016 · Synced Jun 25, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01294306 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →